Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Patient Participation in Thoracic Cancer Clinical Trials

Patient Participation in Thoracic Cancer Clinical Trials EDITORIAL Jean-Louis Pujol, MD,*† Mohammad Chakra, MD,† and Bernard Milleron, MD*‡ 1,2 wo recent articles published in the Journal of Thoracic Oncology are of particular Timportance. It is noteworthy that clinical research is urgently needed in almost all clinical settings of lung cancer from the early stage to metastatic disease. There is a paradox that lung cancer, the leading cause of cancer mortality in both men and women in the developed countries remains the “poor relative” of the clinical cancer research programs with less than 5% of patients enrolling in trials. With a worldwide prognosis remaining almost unchanged during the last decade, it is glaringly obvious that the low participation of patients with thoracic cancer in clinical trials is a major challenge for advancing the field. At the same time, we are facing a dramatic increase in the lung cancer epidemic in many developed countries, particularly in European women, and the situation is worse in many Asian and African countries inasmuch as lung cancer incidence greatly reflects smoking behaviors. Increasing patient participation in thoracic cancer clinical trials is therefore mandatory and the two aforementioned articles help our discussion of this topic: There are four different questions about patients’ participation http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Patient Participation in Thoracic Cancer Clinical Trials

Milleron, Bernard
Journal of Thoracic Oncology , Volume 3 (1) – Jan 1, 2008
Download PDF
3 pages

Loading next page...
 
/lp/wolters-kluwer-health/patient-participation-in-thoracic-cancer-clinical-trials-aWypFpDnkA

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1556-0864
DOI
10.1097/JTO.0b013e31816093ed
pmid
18166833
Publisher site
See Article on Publisher Site

Abstract

EDITORIAL Jean-Louis Pujol, MD,*† Mohammad Chakra, MD,† and Bernard Milleron, MD*‡ 1,2 wo recent articles published in the Journal of Thoracic Oncology are of particular Timportance. It is noteworthy that clinical research is urgently needed in almost all clinical settings of lung cancer from the early stage to metastatic disease. There is a paradox that lung cancer, the leading cause of cancer mortality in both men and women in the developed countries remains the “poor relative” of the clinical cancer research programs with less than 5% of patients enrolling in trials. With a worldwide prognosis remaining almost unchanged during the last decade, it is glaringly obvious that the low participation of patients with thoracic cancer in clinical trials is a major challenge for advancing the field. At the same time, we are facing a dramatic increase in the lung cancer epidemic in many developed countries, particularly in European women, and the situation is worse in many Asian and African countries inasmuch as lung cancer incidence greatly reflects smoking behaviors. Increasing patient participation in thoracic cancer clinical trials is therefore mandatory and the two aforementioned articles help our discussion of this topic: There are four different questions about patients’ participation

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Jan 1, 2008

References

  • The guinea pig syndrome: improving clinical trial participation among thoracic patients
    Quinn
  • An educational video to increase clinical trials enrollment among lung cancer patients
    Du
  • Trends in lung cancer among young European women: the rising epidemic in France and Spain
    Levi
  • Lung cancer epidemiology and risk factors in Asia and Africa
    Lam
  • How sociodemographics, presence of oncology specialists, and hospital cancer program affect accrual to cancer treatment trials
    Sateren
  • Participation in cancer clinical trials: race-, sex-, and age-based disparities
    Murthy
  • UK and USA breast cancer deaths down 25% in year 2000 at ages 20–69 years
    Peto
  • Screening for lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition)
    Bach
  • Lung cancer in the elderly
    Gridelli
  • Weekly paclitaxel combined with monthly carboplatin in elderly patients with advanced non-small cell lung cancer: a multicenter phase II study
    Pujol
  • A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson's index
    Colinet
  • Ethnic disparities in conditional survival of patients with non-small cell lung cancer
    Wang
  • Varying evolution of the New Zealand lung cancer epidemic by ethnicity and socioeconomic position (1981–1999)
    Shaw